IFNA2 and melanoma: Low-dose (LD) IFN-α2b was approved as a first-line therapy for stage II melanoma patients in 1998 based on a trial showing improved 5-year RFS (43% vs. 51%) and a trend toward improved OS (24% vs. 32%) compared to observation [23].